Edition:
United States

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

140.10GBp
7:46am EDT
Change (% chg)

-0.20 (-0.14%)
Prev Close
140.30
Open
140.50
Day's High
141.90
Day's Low
139.50
Volume
681,883
Avg. Vol
1,729,426
52-wk High
177.80
52-wk Low
122.90

Select another date:

Tue, Mar 21 2017

BRIEF-Vectura posts 9-month loss before taxation of 40.1 million stg

* Nine-Month pretax loss 40.1 million stg versus loss of 1.9 million stg for 12 months ended March 31, 2016

BRIEF-Vectura achieves 9 mln stg royalty cap from GSK's Ellipta

* Achieves £9 million royalty cap from gsk ellipta ® products Source text for Eikon: Further company coverage: (Reporting By London Bureau)

BRIEF-Vectura gets $5 mln after an inhaling device hits sales milestone

* Seebri/Ultibro Breezhaler 2016 sales reach $512 mln triggering $5 mln milestone receipt Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-Vectura says U.S. FDA approves IND for paediatric asthma trial

* Fda approves IND to support Vectura's wholly-owned programme VR647 in paediatric asthma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

BRIEF-Vectura's first-half pretax loss widens to 18.6 million

* H1 pretax loss -18.6 million stg versus -2.7 million stg loss year ago Source text for Eikon: Further company coverage: (Reporting By London Bureau)

BRIEF-Hikma announces U.S. deal with Vectura for generic salmeterol development

* Announces agreement with Vectura for development of generic salmeterol for U.S. market Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Vectura on lookout for deals to build specialized lung drug business

LONDON James Ward-Lilley, the former AstraZeneca executive who created a UK respiratory medicine business in June by merging Vectura and SkyePharma, is already thinking about his next deal.

Select another date:

More From Around the Web